Pfizer Anticipates A 'Bolus Of Revenue' From RSV, Prevnar 20 Launches This Year

 
• By Jessica Merrill

Biopharmaceuticals president Angela Hwang said the company is anticipating a strong fourth quarter, driven by the launch of an RSV vaccine and expansion of Prevnar 20 for pediatric use.

vaccine
Pfizer expects new vaccines to deliver a boost to revenues • Source: Shutterstock

More from Earnings

More from Business